不同剂量阿糖胞苷的DA方案治疗CD7抗原阳性急性髓系白血病疗效分析  

Chemotherapeutic effect of two different doses of cytarabine combined with anthracycline for CD7 positive acute myeloid leukemia

作　　者：季素芳[1] 丁韧烨[1] 郭晓珺[1] 

机构地区：[1]嘉兴学院医学院附属第一医院血液科,浙江嘉兴314000

出　　处：《实用肿瘤杂志》2009年第4期378-380,共3页Journal of Practical Oncology

摘　　要：目的探讨含不同剂量阿糖胞苷(Ara-c)的DA方案治疗CD7抗原阳性(CD7+)急性髓系白血病(acute myelocytic leukemia,AML)有效性及安全性。方法回顾性分析45例CD7+AML患者,其中33例采用DA方案化疗,15例用中剂量Ara-c(IDAra-c)1.0g/(m2.12h),d1-3,18例用标准剂量Ara-c100～200mg/(m2.d),d1-5,同时联合蒽环类抗肿瘤药物,观察其完全缓解(complete remission,CR)率,评估其血液、消化道等化疗相关性不良反应。结果33例患者化疗后CR39.4%;含IDAra-c的DA方案治疗组中CR8例(53.3%);部分缓解(PR)2例(13.3%)。18例含标准剂量Ara-c的DA方案治疗组中CR3例(16.7%)(P<0.05);PR4例(22.2%)。含IDAra-c的DA方案常见的不良反应为粒细胞缺乏、恶心、呕吐、脱发、肝功能异常等,但尚能耐受。结论CD7+AML对常规剂量化疗CR相对低,预后较差,含IDAra-c的DA方案有望提高疗效,而其不良反应尚能耐受。Objective To evaluate the chemotherapeutic efficacy and toxicity of two different doses ofcytarabine （Ara-c） comhined with anthracycline for CD7 positive acute myeloict leukemia （CD7^＋ AML）. Methods Thirty-three CD7^＋ AML patients were treated with two DA regimen （Ara-c＋Anthracycline）： Ara-c 100-200mg/（m^2.d）,d1- 5（ID Ara-c） and Ara-c 1.0 g/（m^2. 12 h）,d1-3（ID Ara-c）. The therapeutic efficacy and the safety of these regimen was observed. Results Of the 15 patients receiving ID Ara-c,8 cases achieved complete remission （CR） and 2 partial remission （PR）. Of 18 cases receiving ID Ara-c, 3 cases achieved CR and 4 cases PR, The toxicity included agranulocytosis, nausea, vomiting, alopecia, abnormal liver function. Conclusion ID Ara-c combined with anthracycline is safe and effective for CD7^＋ AML.

关 键 词：白血病 粒细胞 急性/免疫学 白血病 粒细胞 急性/药物疗法 抗原 CD7 抗肿瘤联合化疗方案/治疗应用 免疫表型分型 

分 类 号：R733.71[医药卫生—肿瘤]